CAJ | 학술논문

肺癌是世界上最常见的恶性肿瘤之一，其中非小细胞肺癌约占80%。肝细胞生长因子（hepatocyte growth factor, HGF）/上皮间质转化因子（mesenchymal-epithelial transition factor, MET）信号通路在许多生物学进程中都发挥着多效性影响，然而，在多种类型的肿瘤中都观察到HGF/MET信号通路的异常激活，并且通过生长因子受体和其他致癌性基因受体通路促进细胞增殖和转移。近年来，HGF/MET信号通路的异常激活被认为是对表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）产生耐药的一个重要原因。本文将重点阐述该通路异常激活与非小细胞肺癌患者EGFR-TKI耐药的联系。
폐암시세계상최상견적악성종류지일，기중비소세포폐암약점80%。간세포생장인자（hepatocyte growth factor, HGF）/상피간질전화인자（mesenchymal-epithelial transition factor, MET）신호통로재허다생물학진정중도발휘착다효성영향，연이，재다충류형적종류중도관찰도HGF/MET신호통로적이상격활，병차통과생장인자수체화기타치암성기인수체통로촉진세포증식화전이。근년래，HGF/MET신호통로적이상격활피인위시대표피생장인자수체락안산격매억제제（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）산생내약적일개중요원인。본문장중점천술해통로이상격활여비소세포폐암환자EGFR-TKI내약적련계。
Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. hTe hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF/MET signal pathway activation has been observed in many tumor types, and promotes cellular proliferation and metastasis via growth factor receptors and other oncogenic receptor pathways. In recent years, aberrant HGF/MET signal pathway activation has been considered a key step of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. hTis review addresses how aberrant HGF/MET signal pathway activation being associated with drug resistance to EGFR-TKI therapy in NSCLC patients.